[go: up one dir, main page]

PL2598531T3 - Sposoby i kompozycje do terapii nowotworu wątroby - Google Patents

Sposoby i kompozycje do terapii nowotworu wątroby

Info

Publication number
PL2598531T3
PL2598531T3 PL11738200T PL11738200T PL2598531T3 PL 2598531 T3 PL2598531 T3 PL 2598531T3 PL 11738200 T PL11738200 T PL 11738200T PL 11738200 T PL11738200 T PL 11738200T PL 2598531 T3 PL2598531 T3 PL 2598531T3
Authority
PL
Poland
Prior art keywords
compositions
methods
liver cancer
cancer therapy
therapy
Prior art date
Application number
PL11738200T
Other languages
English (en)
Inventor
Leila Houhou
Anne-Sophie DUMÉ
Dominique Joubert
Frederic Hollande
Original Assignee
Progastrine Et Cancers S.À R.L.
INSERM (Institut National de la Santé et de la Recherche Médicale)
Centre National De La Recherche Scientifique (C.N.R.S.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine Et Cancers S.À R.L., INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (C.N.R.S.) filed Critical Progastrine Et Cancers S.À R.L.
Publication of PL2598531T3 publication Critical patent/PL2598531T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL11738200T 2010-07-26 2011-07-22 Sposoby i kompozycje do terapii nowotworu wątroby PL2598531T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36785110P 2010-07-26 2010-07-26
US201161476204P 2011-04-15 2011-04-15
EP11738200.2A EP2598531B1 (en) 2010-07-26 2011-07-22 Methods and compositions for liver cancer therapy
PCT/EP2011/062686 WO2012013609A1 (en) 2010-07-26 2011-07-22 Methods and compositions for liver cancer therapy

Publications (1)

Publication Number Publication Date
PL2598531T3 true PL2598531T3 (pl) 2021-08-30

Family

ID=45493809

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11738200T PL2598531T3 (pl) 2010-07-26 2011-07-22 Sposoby i kompozycje do terapii nowotworu wątroby

Country Status (16)

Country Link
US (1) US10533050B2 (pl)
EP (1) EP2598531B1 (pl)
JP (1) JP5726305B2 (pl)
KR (1) KR101576174B1 (pl)
CN (1) CN103261224B (pl)
AR (1) AR082340A1 (pl)
AU (1) AU2011284908B2 (pl)
BR (1) BR112013002012A2 (pl)
CA (1) CA2806157C (pl)
EA (2) EA201790882A1 (pl)
ES (1) ES2871092T3 (pl)
NZ (1) NZ606195A (pl)
PL (1) PL2598531T3 (pl)
SG (2) SG187544A1 (pl)
WO (1) WO2012013609A1 (pl)
ZA (1) ZA201300567B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
JP5644110B2 (ja) 2008-08-05 2014-12-24 東レ株式会社 癌の検出方法
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
JP5906739B2 (ja) 2010-02-04 2016-04-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
HUE030130T2 (en) 2011-08-04 2017-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
CN103717740B (zh) 2011-08-04 2015-10-21 东丽株式会社 癌的治疗和/或预防用药物组合物
JP6094220B2 (ja) 2011-08-04 2017-03-15 東レ株式会社 膵臓癌の検出方法
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
KR102005308B1 (ko) 2012-02-21 2019-07-30 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
AU2013223147B2 (en) 2012-02-21 2017-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PL2818482T3 (pl) 2012-02-21 2019-11-29 Toray Industries Kompozycja farmaceutyczna do leczenia nowotworu
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
AU2013241036B2 (en) * 2012-03-30 2017-07-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
BR112015001100A2 (pt) 2012-07-19 2018-03-27 Toray Industries, Inc. método de detecção de câncer
PT2876446T (pt) 2012-07-19 2019-03-25 Toray Industries Método para deteção de cancro
TR201819812T4 (tr) 2013-08-09 2019-01-21 Toray Industries Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim
MX2017003049A (es) * 2014-09-10 2017-05-23 Double Bond Pharmaceuticals Ab Administracion dirigida de farmacos hidrofilicos.
EP3023884A1 (en) * 2014-11-21 2016-05-25 Thomson Licensing Method and apparatus for generating fingerprint of an audio signal
AU2017204686B2 (en) 2015-12-31 2020-04-30 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating esophageal cancer
JP6909795B2 (ja) 2015-12-31 2021-07-28 プロガストリン、エ、カンセル、エス、アー エル、エルＰｒｏｇａｓｔｒｉｎｅ Ｅｔ Ｃａｎｃｅｒｓ Ｓ．Ａ Ｒ．Ｌ． 胃癌の検出および治療のための組成物および方法
MA43550A (fr) 2015-12-31 2018-11-07 Syncerus S A R L Compositions et procédés d'évaluation du risque d'apparition d'un cancer
KR102428254B1 (ko) 2015-12-31 2022-08-03 프로가스트린 에 캔서스 에스.에이 알.엘. 난소암의 검출 및 치료를 위한 조성물 및 방법
EP3601347B1 (en) 2017-03-30 2021-11-03 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
WO2018178364A1 (en) 2017-03-30 2018-10-04 Progastrine Et Cancers S.À R.L. Compositions and methods for treating lung cancer
CA3084687C (en) * 2017-12-05 2024-01-02 Progastrine Et Cancers S.A R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
CN112004560A (zh) 2017-12-08 2020-11-27 Ecs生物识别系统有限公司 癌症诊断中的放射性标记的前胃液素
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
CN112368579B (zh) * 2018-02-27 2024-05-03 Ecs前胃泌素股份有限公司 作为生物标记物的前胃泌素用于免疫疗法
CN114786719A (zh) * 2019-10-02 2022-07-22 阿拉玛布治疗学股份有限公司 抗-连接蛋白抗体制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP2002515458A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 高ガストリン血症の予防および処置
AU2002326356A1 (en) * 2001-07-09 2003-01-29 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
EP1631236A2 (en) * 2003-06-02 2006-03-08 Alexion Pharmaceuticals, Inc. Cell surface protein associated with human chronic lymphocytic leukemia
US8158128B2 (en) * 2004-09-22 2012-04-17 Cancer Advances, Inc. Monoclonal antibodies to progastrin
CA2652768A1 (en) * 2006-05-22 2007-11-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibitors of progastrin-induced repression of icat for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells andcells in which the beta-catenin/tcf-4-mediated transcriptional pathway is constitutively active
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
IN2012DN03348A (pl) * 2009-10-16 2015-10-23 Biorealites
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
AU2011231978B2 (en) * 2010-03-24 2014-12-18 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer

Also Published As

Publication number Publication date
ES2871092T3 (es) 2021-10-28
JP2013533277A (ja) 2013-08-22
SG10201703556YA (en) 2017-06-29
EP2598531A1 (en) 2013-06-05
CN103261224B (zh) 2015-10-07
KR20130083438A (ko) 2013-07-22
AU2011284908A1 (en) 2013-02-07
KR101576174B1 (ko) 2015-12-09
AR082340A1 (es) 2012-11-28
ZA201300567B (en) 2014-03-26
EA028515B1 (ru) 2017-11-30
EA201300171A1 (ru) 2013-07-30
EP2598531B1 (en) 2020-12-30
JP5726305B2 (ja) 2015-05-27
US20120020961A1 (en) 2012-01-26
EA201790882A1 (ru) 2017-08-31
US10533050B2 (en) 2020-01-14
CN103261224A (zh) 2013-08-21
BR112013002012A2 (pt) 2019-08-27
SG187544A1 (en) 2013-03-28
AU2011284908B2 (en) 2015-05-21
CA2806157A1 (en) 2012-02-02
NZ606195A (en) 2015-02-27
CA2806157C (en) 2016-11-22
WO2012013609A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
ZA201300567B (en) Methods and compositions for liver cancer therapy
IL258740B (en) Combined liposome preparations for cancer treatment
IL227429A0 (en) The components and methods of cancer treatment
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
EP2640359A4 (en) NEW COMPOSITIONS AND USES OF BLOOD PRESSURE RECIPROCATORS FOR CANCER THERAPY
EP2734207A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
WO2012009611A9 (en) Methods and compositions for cancer immunotherapy
EP2643045A4 (en) THERAPEUTIC PROCESSES AND COMPOSITIONS FOR SOLID FORM DELIVERY
SG10201500124VA (en) Methods and Compositions for Treating Cancer
PT2558095T (pt) Composto orgânico para utilização no tratamento do cancro hepático
IL251083B (en) Compounds and preparations for the treatment of cancer
EP2655309A4 (en) METHODS AND COMPOSITIONS FOR TREATING LUNG CANCER
PL2605764T3 (pl) Kompozycje do leczenia nowotworu
IL232466A (en) Preparations and Methods for Prostate Cancer Analysis
IL229231A0 (en) Preparations and methods for the treatment of cancer
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
EP2585115A4 (en) CANCER THERAPY
EP2582384A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2537031A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
IL225959A0 (en) Methods and preparations for diagnosis and treatment @ בסרטן
EP2632494A4 (en) METHOD AND COMPOSITIONS FOR THE STUDY AND TREATMENT OF CANCER
GB201003741D0 (en) Methods and therapeutic compositions
GB201011456D0 (en) Compositions and methods for embolization therapy
GB201020513D0 (en) Cancer therapy